Table 2.
Single agent results in early phases of clinical trials.
| Drug | Patients treated | Disease control rate a | Major treatment-related toxicities | Reference |
|---|---|---|---|---|
| MK0752 | 103 | 1 CR in anaplastic astrocytoma, 15 SDs in mostly GBM | GI disorders, fatigue, AST increase, rash | Krop et al., 2012; |
| RO4929097 | 110 | 1 PR in colorectal adenocarcinoma with neuroendocrine features, 26 SDs in sarcoma, melanoma or ovarian cancer | GI events, fatigue, hypophosphatemia, rash | Tolcher et al, 2012; |
| PF03084014 | 41 | 1 CR in papillary thyroid cancer, 4 PRs in desmoid tumors | Diarrhea, nausea, rash and fatigue | Messersmith et al, 2012 |
| OMP-59R5 | 39 | SDs in adenoid cystic adenocarcinoma, sarcomas, rectal cancer, or triple-negative breast cancer | Diarrhea | Smith et al, 2012 |
| REGN421 | 53 | 2 PRs in NSCLC and ovarian cancer, 16 SDs | Fatigue, headache, hypertension, nausea | Jimeno et al, 2013 |
a
Disease control rate includes complete and partial responses, and stable disease.